|
Adult T-Cell Lymphoma/Leukemia
|
0.310 |
Biomarker
|
disease |
CTD_human |
Integrated molecular analysis of adult T cell leukemia/lymphoma.
|
26437031 |
2015 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
|
23334668 |
2013 |
|
Adult T-Cell Lymphoma/Leukemia
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
HELIOS-BCL11B fusion gene involvement in a t(2;14)(q34;q32) in an adult T-cell leukemia patient.
|
22867996 |
2012 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.310 |
AlteredExpression
|
disease |
LHGDN |
Overexpression of novel short isoforms of Helios in a patient with T-cell acute lymphoblastic leukemia.
|
11937265 |
2002 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
In contrast, low-hypodiploid ALL with 32-39 chromosomes are characterized by alterations in TP53 (91.2%) that are commonly present in nontumor cells, IKZF2 (encoding HELIOS; 53%) and RB1 (41%).
|
23334668 |
2013 |
|
L2 Acute Lymphoblastic Leukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
|
23334668 |
2013 |
|
Eczema
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Serum gamma-glutamyl transferase measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Biomarker and Genomic Risk Factors for Liver Function Test Abnormality in Hazardous Drinkers.
|
30589442 |
2019 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations.
|
29293537 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus.
|
27399966 |
2016 |
|
Eosinophil count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Blood basophil count (lab test)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus.
|
26502338 |
2015 |
|
Chronic Lymphocytic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Data reviewed here include: preliminary results from CLL12, long-term results of CLL8 and MD Anderson Cancer Center (MDACC) data with FCR, 7-year follow-up of PCYC-1102/1103 (phase 2 data) with ibrutinib, results of two-phase 3 randomized trials comparing CIT to ibrutinib, E1912 and A041202, and results of HELIOS and other phase 2 trials evaluating CIT combined with ibrutinib.<b>Expert opinion</b>: Treatment approaches for patients with CLL should be individualized and that there is still a role, albeit diminished, for CIT in the treatment of CLL, predominately in the front-line setting.
|
31756301 |
2020 |
|
Chronic Lymphocytic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p.
|
30315239 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.
|
29295653 |
2018 |
|
Recurrent Chronic Lymphoid Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
|
30315239 |
2019 |
|
Small Lymphocytic Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p.
|
30315239 |
2019 |
|
Recurrent Chronic Lymphoid Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.
|
29295653 |
2018 |
|
Small Lymphocytic Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.
|
29295653 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, our study shows that IKZF2 regulates the AML LSC program and provides a rationale to therapeutically target IKZF2 in myeloid leukemia.
|
30472158 |
2019 |
|
Acute Undifferentiated Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation.
|
30472158 |
2019 |
|
Leukemogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
IKZF2 depletion in acute myeloid leukemia (AML) cells reduced colony formation, increased differentiation and apoptosis, and delayed leukemogenesis.
|
30472158 |
2019 |